109 related articles for article (PubMed ID: 22459309)
1. Usefulness of intravenous adenosine in idiopathic pulmonary arterial hypertension as a screening agent for identifying long-term responders to calcium channel blockers.
Zuo XR; Zhang R; Jiang X; Li XL; Zong F; Xie WP; Wang H; Jing ZC
Am J Cardiol; 2012 Jun; 109(12):1801-6. PubMed ID: 22459309
[TBL] [Abstract][Full Text] [Related]
2. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension.
Jing ZC; Jiang X; Han ZY; Xu XQ; Wang Y; Wu Y; Lv H; Ma CR; Yang YJ; Pu JL
Eur Respir J; 2009 Jun; 33(6):1354-60. PubMed ID: 19213781
[TBL] [Abstract][Full Text] [Related]
3. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.
Sitbon O; Humbert M; Jaïs X; Ioos V; Hamid AM; Provencher S; Garcia G; Parent F; Hervé P; Simonneau G
Circulation; 2005 Jun; 111(23):3105-11. PubMed ID: 15939821
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertension.
Tonelli AR; Alnuaimat H; Mubarak K
Respir Med; 2010 Apr; 104(4):481-96. PubMed ID: 20004088
[TBL] [Abstract][Full Text] [Related]
5. Outcomes in children with idiopathic pulmonary arterial hypertension.
Yung D; Widlitz AC; Rosenzweig EB; Kerstein D; Maislin G; Barst RJ
Circulation; 2004 Aug; 110(6):660-5. PubMed ID: 15289375
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Vascular Capacitance is Associated with Vasoreactivity and Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension.
Cheng XL; He JG; Liu ZH; Gu Q; Ni XH; Zhao ZH; Luo Q; Xiong CM
Lung; 2016 Aug; 194(4):613-8. PubMed ID: 27272652
[TBL] [Abstract][Full Text] [Related]
8. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.
Sitbon O; Humbert M; Jagot JL; Taravella O; Fartoukh M; Parent F; Herve P; Simonneau G
Eur Respir J; 1998 Aug; 12(2):265-70. PubMed ID: 9727772
[TBL] [Abstract][Full Text] [Related]
9. Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria.
Douwes JM; van Loon RL; Hoendermis ES; Vonk-Noordegraaf A; Roofthooft MT; Talsma MD; Hillege HL; Berger RM
Eur Heart J; 2011 Dec; 32(24):3137-46. PubMed ID: 21893489
[TBL] [Abstract][Full Text] [Related]
10. Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry.
Douwes JM; Humpl T; Bonnet D; Beghetti M; Ivy DD; Berger RM;
J Am Coll Cardiol; 2016 Mar; 67(11):1312-23. PubMed ID: 26988953
[TBL] [Abstract][Full Text] [Related]
11. Acute vasoreactivity testing with nicardipine in patients with pulmonary arterial hypertension.
Saito Y; Nakamura K; Miyaji K; Akagi S; Mizoguchi H; Ogawa A; Fuke S; Fujio H; Kiyooka T; Nagase S; Kohno K; Morita H; Kusano KF; Matsubara H; Ohe T; Ito H
J Pharmacol Sci; 2012; 120(3):206-12. PubMed ID: 23117888
[TBL] [Abstract][Full Text] [Related]
12. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era.
Gerhardt F; Fiessler E; Olsson KM; Kayser MZ; Kovacs G; Gall H; Ghofrani HA; Badr Eslam R; Lang IM; Benjamin N; Grünig E; Halank M; Lange TJ; Ulrich S; Leuchte H; Held M; Klose H; Ewert R; Wilkens H; Pizarro C; Skowasch D; Wissmüller M; Hellmich M; Olschewski H; Hoeper MM; Rosenkranz S
Circulation; 2024 May; 149(20):1549-1564. PubMed ID: 38606558
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders.
Halliday SJ; Hemnes AR; Robbins IM; Pugh ME; Zhao DX; Piana RN; Fong PP; Brittain EL
J Heart Lung Transplant; 2015 Mar; 34(3):312-8. PubMed ID: 25577565
[TBL] [Abstract][Full Text] [Related]
14. [Pulmonary arterial hypertension treated with prostacyclin or calcium blockers].
Andreassen AK; Geiran O; Madsen S; Hognestad A; Simonsen S
Tidsskr Nor Laegeforen; 2003 Dec; 123(23):3393-6. PubMed ID: 14713978
[TBL] [Abstract][Full Text] [Related]
15. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension.
Montani D; Savale L; Natali D; Jaïs X; Herve P; Garcia G; Humbert M; Simonneau G; Sitbon O
Eur Heart J; 2010 Aug; 31(15):1898-907. PubMed ID: 20543192
[TBL] [Abstract][Full Text] [Related]
16. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
17. The role of calcium channel blockers for the treatment of pulmonary arterial hypertension: How much do we actually know and how could they be positioned today?
Medarov BI; Judson MA
Respir Med; 2015 May; 109(5):557-64. PubMed ID: 25666253
[TBL] [Abstract][Full Text] [Related]
18. Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension.
Sandqvist A; Henrohn D; Egeröd H; Hedeland M; Wernroth L; Bondesson U; Schneede J; Wikström G
Eur J Clin Pharmacol; 2015 Oct; 71(10):1165-73. PubMed ID: 26242227
[TBL] [Abstract][Full Text] [Related]
19. Comparison of baseline characteristics and survival between patients with idiopathic and connective tissue disease-related pulmonary arterial hypertension.
Ruiz-Cano MJ; Escribano P; Alonso R; Delgado J; Carreira P; Velazquez T; Sanchez MA; Sáenz de la Calzada C
J Heart Lung Transplant; 2009 Jun; 28(6):621-7. PubMed ID: 19481024
[TBL] [Abstract][Full Text] [Related]
20. Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension.
Zhang DZ; Zhu XY; Meng J; Xue HM; Sheng XT; Han XM; Cui CS; Wang QG; Zhang P
Int J Cardiol; 2011 Mar; 147(3):433-7. PubMed ID: 20537740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
